newsfilter
← Latest News
Business Wire·

Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK® Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data Investigationa